



Anti-tubercular and antioxidant activities of C-glycosyl carbonic anhydrase inhibitors: towards the development of novel chemotherapeutic agents against *Mycobacterium tuberculosis*

María J. Zaro, Ana Bortolotti, Leonardo E. Riafrecha, Analía Concellón, Héctor R. Morbidoni & Pedro A. Colinas

To cite this article: María J. Zaro, Ana Bortolotti, Leonardo E. Riafrecha, Analía Concellón, Héctor R. Morbidoni & Pedro A. Colinas (2016) Anti-tubercular and antioxidant activities of C-glycosyl carbonic anhydrase inhibitors: towards the development of novel chemotherapeutic agents against *Mycobacterium tuberculosis*, Journal of Enzyme Inhibition and Medicinal Chemistry, 31:6, 1726-1730, DOI: [10.3109/14756366.2016.1172577](https://doi.org/10.3109/14756366.2016.1172577)

To link to this article: <https://doi.org/10.3109/14756366.2016.1172577>



Published online: 05 May 2016.



Submit your article to this journal [↗](#)



Article views: 687



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 2 View citing articles [↗](#)

SHORT COMMUNICATION

Anti-tubercular and antioxidant activities of C-glycosyl carbonic anhydrase inhibitors: towards the development of novel chemotherapeutic agents against *Mycobacterium tuberculosis*

María J. Zaro^{1*}, Ana Bortolotti^{2*}, Leonardo E. Riafrecha^{3*}, Analía Concellón¹, Héctor R. Morbidoni², and Pedro A. Colinas³

¹CIDCA (Centro de Investigación y Desarrollo en Criotecología de Alimentos, CCT La Plata-CONICET, UNLP), La Plata, Argentina, ²Laboratorio de Microbiología Molecular, Cátedra de Microbiología, Virología y Parasitología; Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina, and ³LADECOR CONICET, Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina

Abstract

During the treatment of tuberculosis infection, oxidative stress due to anti-tubercular drugs may result in tissue inflammation. It was suggested that treatment with antioxidant drugs could be beneficial as an adjunct to anti-tuberculosis drug therapy. Recently our group has shown that several C-glycosides are inhibitors of *Mycobacterium tuberculosis* β -carbonic anhydrases (CAs, EC 4.2.1.1). In an effort to develop novel chemotherapeutic agents against tuberculosis, the anti-tubercular and antioxidant activities of a series of C-glycosides containing the phenol or the methoxyaryl moiety were studied. Many compounds showed inhibition of growth of *M. tuberculosis* H₃₇Rv strain and good antioxidant ability. A glycomimetic incorporating the 3-hydroxyphenyl moiety showed the best activity profile and therefore this functionality represents lead for the development of novel anti-tubercular agents with dual mechanisms of action.

Introduction

Infection with *Mycobacterium tuberculosis* and related mycobacteria affects a large fraction of the world population, with an estimated 9.4 million new cases and 1.7 million deaths annually¹. Furthermore, tuberculosis (TB) infection including both multi-drug-resistant tuberculosis (MDR-TB) and drug-resistant tuberculosis (XDR-TB) is a leading cause of death worldwide. The development of novel anti-TB drugs that do not possess cross-resistance with current anti-mycobacterial drugs and have minimal toxicity, is urgently needed due to the increasing incidence of MDR-TB, XDR-TB and TB-HIV co-infection. In the last 20 years, the research on *M. tuberculosis* has made much progress with the genome deciphered² and the discovery of possible new drug targets which may lead to the development of compounds possessing a novel mechanism of action, thus helping solve the drug resistance problem mentioned above^{3,4}. Among the new such

Keywords

Dual mechanism, glycomimetic, tuberculosis

History

Received 8 March 2016
Revised 21 March 2016
Accepted 23 March 2016
Published online 3 May 2016

proteins identified after the *M. tuberculosis* genome was published, there are three β -carbonic anhydrases (CAs, EC 4.2.1.1) which have been cloned, purified and characterized by Jones' and Supuran's groups. Several sulfonamide and sulfamate inhibitors of the three mycobacterial carbonic anhydrases have been reported⁵.

During the treatment of TB infection, oxidative stress may result in tissue inflammation due to anti-tubercular drugs⁶. Recently it has been shown that oxidative stress conditions exist in the guinea pig model of TB, similar to what is seen in humans. The systemic and tissue oxidative stress is progressive and correlates with the loss of Nrf2 mediated antioxidant defense mechanisms. Considering the importance of lung lesion progression and the extra-pulmonary dissemination of bacilli in TB pathogenesis, it was suggested that treatment with antioxidant drugs could be beneficial as an adjunct to anti-tuberculosis drug therapy. An added benefit of antioxidant treatment of patients with TB is the reduction of the toxic side effects of anti-tuberculosis drug therapy, mediated in part by the generation of oxygen free radical in the liver⁷.

These observations led us to propose that the combination of antioxidant activity and mtCAs inhibition might result in novel anti-tubercular agents with dual mechanisms of action. Our strategy towards these dual acting compounds was based on the synthesis of C-glycosides where the carbohydrate moiety is tethered to a phenol or methoxyaryl CA pharmacophore through a carbon chain.

*These authors participated equally in this work.

Address for correspondence: Héctor R. Morbidoni, Laboratorio de Microbiología Molecular, Cátedra de Microbiología, Virología y Parasitología; Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe 3100, Rosario, (2000), Argentina. E-mail: morbiatny@yahoo.com

Pedro A. Colinas, LADECOR CONICET, Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 47 y 115, La Plata, (1900), Argentina. E-mail: pcolinas@quimica.unlp.edu.ar

The replacement of the naturally occurring O-glycoside bond by *C*-glycoside bond is an approach practiced in the synthesis of carbohydrate-containing compounds for the downstream biological applications⁸. This isosteric replacement seeks to enhance stability of the small molecule glycoside toward enzymatic hydrolysis of the glycosidic bond while retaining vital molecular recognition interactions with the biological target⁹.

The use of glycomimetics in the design of carbonic anhydrase inhibitors (CAIs) has proven to be a successful approach and now constitutes one of the most attractive ways to develop new generations of effective and selective inhibitors^{8,10}. Recently one of our groups has applied the "sugar approach" to the preparation of *C*-cinnamoyl phenols, where the carbohydrate moiety is tethered to a phenol CA pharmacophore through a carbon chain¹¹. These compounds have been tested as inhibitors of the *Mycobacterium tuberculosis* β -CAs and have shown better inhibitory activity against mtCAs than phenol. Also the anti-tubercular activity of the *C*-glycosyl phenols was investigated, allowing us to identify the first mtCAs inhibitor with antimycobacterial activity¹². These glycosides also showed to be very good

inhibitors of *Brucella suis* CAs¹³. Very recently we have developed a novel series of *C*-glycosides containing the methoxyaryl scaffold and investigated them as inhibitors against human and fungal isozymes of carbonic, showing that some of them are potent and highly selective inhibitors^{14,15}. It should be pointed out that only very recently methoxyphenyl derivatives have been investigated as CAIs because it was considered that they do not bear any moiety normally associated with CA inhibition in their molecules.

The aim of the present work was to study the anti-tubercular and antioxidant activity of a series of *C*-glycosides that could be useful for the development of novel chemotherapeutic agents against TB.

Materials and methods

Synthesis of *C*-glycosides

C-glycosides **1–20** were previously described and have been prepared by aldol reaction of aryl aldehydes with per-*O*-acetylated




Figure 1. Peracetylated *C*-glycosides (**1–4**) and fully deprotected derivatives (**5–8**) containing the phenol moiety.




Figure 2. Per-*O*-acetylated *C*-glycosides (**9–14**) and fully deprotected derivatives (**15–20**) containing the methoxyaryl moiety.

C-glucosyl or C-galactosyl ketones and subsequent deprotection using triethylamine in methanol/water^{11,14}.

Anti-mycobacterial activity assay

Bacterial strains and growth media: *Mycobacterium tuberculosis* strain H₃₇Rv was grown in Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI) supplemented with 1/10 v/v of ADS (a solution containing 50 g/L BSA fraction V, 20 g/L dextrose and 8.1 g/L NaCl), glycerol (1% w/v) herein designated 7H9-ADS-G for short. Tween 80 (0.05% w/v) was added to prevent clumping. When needed, solid media (Middlebrook 7H11) supplemented with ADS (1/10 v/v) and glycerol (1% v/v) was used. Cultures were grown at 37 °C under gentle agitation.

Stock solutions for all the tested compounds were made in DMSO at 10 mg/mL. Working solutions were made by dilution in the above described 7H9-ADS-G medium at a final concentration of 400 µg/mL.

Antimycobacterial activity was determined by a two-fold dilution of the compounds in Middlebrook 7H9-ADS-G medium. For this purpose 96-well plates (Falcon, Cat number 3072, Becton Dickinson, Lincoln Park, NJ) were used. The 96-well plates received 100 µL of Middlebrook 7H9 broth and a serial two-fold dilution of the compounds was made directly on the plate. The initial and final drug concentrations tested were 100 and 0.78 µg/mL, respectively. Four compounds were tested in duplicate in each microtiter plate, Rifampicin (from 2 to 0.16 µg/mL; stock solution prepared as a 10 mg/mL solution in methanol) was used as control drug. Two rows were used for growth control (medium and inoculum alone) and sterility control (medium alone). The inoculum was prepared as a 1/25 dilution of a fresh mid-log *M. tuberculosis* H₃₇Rv suspension (O.D equivalent to Mc Farland 1.0 scale value) made in Middlebrook 7H9-ADS-G. A 100-µL aliquot (containing approximately 10⁶ Colony Forming Units) was used to inoculate the wells except for the row used for sterility testing. Plates were sealed with Parafilm and incubated at 37 °C for seven days. Minimum inhibitory concentration (MIC) was defined as the lowest drug concentration preventing mycobacterial growth as judged by visual inspection.

Antioxidant capacity


Stock solutions of the samples were prepared dissolving 15 mg of the tested compounds in 100 µL DMSO (1 mM) and then homogenizing with absolute methanol until a final volume of 1000 µL. The antioxidant capacity (AC) was determined by two different methods: DPPH and ABTS radical scavenging assays¹⁶.

The ABTS assay is based on the ability of samples to quench the stable cation radical 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS^{•+}) with the consequent discoloration of the blue/green solution when compared to the absorbance of a blank. Briefly, 10 µL of sample were added to 1 mL ABTS^{•+} working solution (absorbance of 0.700 ± 0.02 at 734 nm), incubated for 6 min at room temperature and the reduction of absorbance at 734 nm was recorded in a spectrophotometer (Thermo Scientific, Waltham, MA, Evolution 60S). In the DPPH assay, the capacity of the sample to reduce the stable and purple radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) to the yellow-colored diphenylpicrylhydrazine was determined. Aliquots of sample (100 µL) were added to test tubes containing 150 µL of 40 mg/L DPPH ethanolic solution. The absorbance reduction at 515 nm was measured until the reaction reached a plateau (60 min). Corresponding blanks were used to determine the stability of the DPPH[•] solution. For both assays, Trolox was used as antioxidant standard and results were expressed as percentage of radical inhibition per 0.1 mg (for ABTS assay) or 1 mg (for DPPH assay) of tested compounds. Measures were done in triplicate.

Results and discussion

A set of C-cinnamoyl glycosides (Figures 1 and 2) was synthesized as outlined in Scheme 1 and described previously by us^{11,14}. C-cinnamoyl glycosides **1–4** and **9–14** have been prepared by aldol condensation of β-C-glucosyl and β-C-galactosyl ketones with aryl aldehydes at room temperature in the presence of pyrrolidine as catalyst (Scheme 1). The O-acetate protecting groups of the carbohydrate moiety were next removed using triethylamine in methanol/water to afford the deprotected C-glycosides **5–8** and **15–20**. All the glycomimetics prepared have been previously tested against human, bacterial and fungal CAs and showed very good inhibition profiles^{11–15}. The anti-tubercular activity of compounds **1–20** was investigated by using fresh cultures of *M. tuberculosis* H₃₇Rv grown and tested as previously described. Tests were carried on by duplicate. Our results clearly demonstrated that compounds **1**, **2**, **6**, **7** and **10** displayed growth inhibition activity at concentrations between 50 and 100 µg/mL (Table 1).

Due to their promising anti-tubercular activity, it was advisable to evaluate the antioxidant activity of the compounds we synthesized. We performed DPPH and ABTS radical scavenging assays as they are the most commonly used methods for screening antioxidant activities of the various natural as well as synthetic antioxidants. The results are summarized in Figures 3 and 4.



Scheme 1. Preparation of C-cinnamoyl glycosides **1–20**.



Table 1. Anti-tubercular activity of C-glycosides 1–20.

Compound	Concentration		
	100 µg/mL	50 µg/mL	≤25 µg/mL
1*	Yes† (++++‡)	Yes (+++)	No
2*	Yes (++)	Yes (+)	No
3*	No	No	No
4*	No	No	No
5*	No	No	No
6*	Yes (++)	Yes (+)	No
7*	Yes (++)	Yes (+)	No
8*	No	No	No
9	No	No	No
10	Yes (+++)	Yes (++)	No
11	No	No	No
12	No	No	No
13	No	No	No
14	No	No	No
15	No	No	No
16	No	No	No
17	No	No	No
18	No	No	No
19	No	No	No
20	No	No	No

*From Reference¹².

†Yes indicates inhibition of growth, as judged by turbidity.

‡Extent of inhibition (++) > (+) > (+).

Figure 3. Percent inhibition of the DPPH• radical by tested compounds (1 mg). Standard deviation is shown ($n = 3$).Figure 4. Percent inhibition of the ABTS•+ radical by tested compounds (0.1 mg). Standard deviation is shown ($n = 3$).

A number of structure–activity relationships (SARs) were identified in this study and are summarized as follows.

- (i) The C-glycosides containing the phenol moiety showed good radical scavenging activity. Also the glycomimetics showed better ability compared to the glycosyl ketones used in their preparation, showing that attaching of the phenyl moiety improves its scavenging activity. It should be noted that all deprotected glycomimetics glycosyl exhibited better activity than the per-O-acetylated derivatives. Galactosides 3 and 7, which possess a hydroxyl group at *meta* position of phenyl ring, showed less antioxidant activity as compared to glucosides 1 and 5, with the same substitution at the aromatic moiety. A closely related situation was found with the glycosides containing a –OH at *para* position of the phenyl ring, with the exception of compound 8. It is significant to note that the compounds showing anti-tubercular activity also showed a moderate to good radical scavenging activity.
- (ii) Some C-glycosides incorporating the methoxyaryl moiety showed interesting antioxidant activity. In the 6-methoxy-naphthyl series only derivate 17 showed moderate radical scavenging activity. Glicosyl derivatives of veratraldehyde 13, 16 and 19 exhibited good antioxidant ability showing that this moiety could be useful in the design of novel sugar antioxidants. It is interesting to note that galactoside 10,

which possesses a very low antioxidant activity, is the only methoxyaryl derivative that showed anti-tubercular activity.

In conclusion, we have investigated the antioxidant and anti-tubercular activities of C-glycosides incorporating the phenol or methoxyaryl moieties. The 3-hydroxyphenyl glycoside (compound **1**) exhibited good anti-tubercular and antioxidant activities showing that this moiety therefore represents a lead for the development of novel anti-tubercular agents with dual mechanisms of action.

Declaration of interest

The authors report no declarations of interest. This work was financed in part by the Agencia Nacional de Promoción Científica y Tecnológica (PICT-O GSK0016 and PICT2012-2803), and by UNLP and CONICET (PIP 0701). HRM is a member of Universidad Nacional de Rosario Research Council (CIUNR). A.C., A.B. and P.A.C are members of the Scientific Research Career of CONICET.

References

1. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. *Nat Rev Microbiol* 2009;7:81–7.
2. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 1998;393:537–44.
3. Wilson R, Kumar P, Parashar V, et al. Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. *Nat Chem Biol* 2013;9:499–506.
4. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. *Curr Med Chem* 2008;15:1956–67.
5. Nishimori I, Minakuchi T, Maresca A, et al. The β -carbonic anhydrases from *Mycobacterium tuberculosis* as drug targets. *Curr Pharm Des* 2010;16:3300–9.
6. Palanisamy GS, Kirk NM, Ackart DF, et al. Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis. *PLoS One* 2011;6:e26254.
7. Nanashima K, Mawatari T, Tahara N, et al. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. *Tuberculosis* 2012;92:253–9.
8. Colinas PA. Novel glycomimetics: anomeric and N-glycosyl sulfonamides. *Curr Org Chem* 2012;16:1670–6.
9. Asensio JL, Cañada FJ, Cheng X, et al. Conformational differences between O- and C-glycosides: the α -O-Man-(1 \rightarrow 1)- β -Gal/ α -C-Man-(1 \rightarrow 1)- β -Gal case—a decisive demonstration of the importance of the exo-anomeric effect on the conformation of glycosides. *Chem Eur J* 2000;6:1035–41.
10. Winum JY, Colinas PA, Supuran CT. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. *Bioorg Med Chem* 2013;21:1419–26.
11. Riafrecha LE, Rodríguez OM, Vullo D, et al. Synthesis of C-cinnamoyl glycosides and their inhibitory activity against mammalian carbonic anhydrases. *Bioorg Med Chem* 2013;21:1489–94.
12. Buchieri MV, Riafrecha LE, Rodríguez OM, et al. Inhibition of the β -carbonic anhydrases from *Mycobacterium tuberculosis* with C-cinnamoyl glycosides: identification of the first inhibitor with anti-mycobacterial activity. *Bioorg Med Chem Lett* 2013;23:740–3.
13. Riafrecha LE, Vullo D, Ouahrani-Bettache S, et al. Inhibition of β -carbonic anhydrases from *Brucella suis* with C-cinnamoyl glycosides incorporating the phenol moiety. *J Enzyme Inhib Med Chem* 2015;30:1017–20.
14. Riafrecha LE, Rodríguez OM, Vullo D, et al. Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII. *Bioorg Med Chem* 2014;22:5308–14.
15. Riafrecha LE, Vullo D, Supuran CT, Colinas PA. C-glycosides incorporating the 6-methoxy-2-naphthyl moiety are selective inhibitors of fungal and bacterial carbonic anhydrases. *J Enzyme Inhib Med Chem* 2015;30:857–61.
16. Zaro MJ, Chaves AR, Vicente AR, Concellón A. Distribution, stability and fate of phenolic compounds in white and purple eggplants (*Solanum melongena* L.). *Postharvest Biol Technol* 2014;92:70–8.